Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Postpartum Nurses' Experience Caring for Infants With Neonatal Abstinence Syndrome.

Loyal J, Nguyen VN, Picagli D, Petrucelli A, O'Mara E, Grossman MR, Colson E.

Hosp Pediatr. 2019 Aug;9(8):601-607. doi: 10.1542/hpeds.2019-0087. Epub 2019 Jul 22.

PMID:
31331933
2.

Newborn Falls in a Large Tertiary Academic Center Over 13 Years.

Loyal J, Pettker CM, Raab CA, O'Mara E, Lipkind HS.

Hosp Pediatr. 2018 Sep;8(9):509-514. doi: 10.1542/hpeds.2018-0021. Epub 2018 Aug 1.

PMID:
30068526
3.

Change in drawing placement: A measure of change in mood state reflective of hemispheric lateralization of emotion.

Butler TR, O'Mara EM, Wilson JF.

Brain Cogn. 2018 Jul;124:14-19. doi: 10.1016/j.bandc.2018.04.004.

PMID:
29705618
4.

Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.

Yeh WW, Fraser IP, Jumes P, Petry A, Lepeleire I, Robberechts M, Reitmann C, Van Dyck K, Huang X, Guo Z, Panebianco D, Nachbar RB, O'Mara E, Wagner JA, Butterton JR, Dutko FJ, Moiseev V, Kobalava Z, Hüser A, Visan S, Schwabe C, Gane E, Popa S, Ghicavii N, Uhle M, Wagner F.

Clin Ther. 2018 May;40(5):704-718.e6. doi: 10.1016/j.clinthera.2018.03.002. Epub 2018 Apr 25.

PMID:
29703432
5.

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S.

Clin Pharmacol. 2017 Nov 8;9:133-145. doi: 10.2147/CPAA.S144606. eCollection 2017.

6.

Does self-enhancement facilitate task performance?

O'Mara EM, Gaertner L.

J Exp Psychol Gen. 2017 Mar;146(3):442-455. doi: 10.1037/xge0000272.

PMID:
28253012
7.

Erratum for Kersemaekers et al., Pharmacokinetics and Safety Study of Posaconazole Intravenous Solution Administered Peripherally to Healthy Subjects.

Kersemaekers WM, van Iersel T, Nassander U, O'Mara E, Waskin H, Caceres M, van Iersel ML.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4426. doi: 10.1128/AAC.01001-16. Print 2016 Jul. No abstract available.

8.

A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects.

Mondal SA, Assaf M, Liu L, O'Mara E.

Cancer Chemother Pharmacol. 2016 Feb;77(2):251-8. doi: 10.1007/s00280-015-2912-7. Epub 2016 Jan 11.

PMID:
26754679
9.

Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.

Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O'Mara E, Rogge M, Stoch SA, Robertson SM.

J Clin Pharmacol. 2016 Feb;56(2):143-51. doi: 10.1002/jcph.562. Epub 2015 Jul 29. Review.

PMID:
26044116
10.

A fit for purpose training programme for the decontamination of personnel.

O'Mara E, Cole P, Wynn A, Collison R.

J Radiol Prot. 2015 Jun;35(2):249-56. doi: 10.1088/0952-4746/35/2/249. Epub 2015 Mar 13.

PMID:
25769116
11.

Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy.

Hulskotte EG, Bruce RD, Feng HP, Webster LR, Xuan F, Lin WH, O'Mara E, Wagner JA, Butterton JR.

Eur J Clin Pharmacol. 2015 Mar;71(3):303-11. doi: 10.1007/s00228-014-1789-4. Epub 2015 Feb 11.

PMID:
25666027
12.

Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects.

Kersemaekers WM, van Iersel T, Nassander U, O'Mara E, Waskin H, Caceres M, van Iersel ML.

Antimicrob Agents Chemother. 2015 Feb;59(2):1246-51. doi: 10.1128/AAC.04223-14. Epub 2014 Dec 15. Erratum in: Antimicrob Agents Chemother. 2016 Jul;60(7):4426.

13.

The effect of collaboration on obstetric patient safety in three academic facilities.

Raab CA, Will SE, Richards SL, O'Mara E.

J Obstet Gynecol Neonatal Nurs. 2013 Sep-Oct;42(5):606-16. doi: 10.1111/1552-6909.12234. Epub 2013 Sep 4.

PMID:
24004008
14.

Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.

Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR.

Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8. doi: 10.1128/AAC.02347-12. Epub 2013 Mar 25.

15.

Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.

Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC, Currie BJ, Dance D, Gee JE, Larsen J, Limmathurotsakul D, Morrow MG, Norton R, O'Mara E, Peacock SJ, Pesik N, Rogers LP, Schweizer HP, Steinmetz I, Tan G, Tan P, Wiersinga WJ, Wuthiekanun V, Smith TL.

Emerg Infect Dis. 2012 Dec;18(12):e2. doi: 10.3201/eid1812.120638.

16.

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.

Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, Butterton JR.

Clin Infect Dis. 2013 Mar;56(5):718-26. doi: 10.1093/cid/cis968. Epub 2012 Nov 15.

PMID:
23155151
17.

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.

Krishna G, Ma L, Martinho M, Preston RA, O'Mara E.

J Antimicrob Chemother. 2012 Nov;67(11):2725-30. doi: 10.1093/jac/dks268. Epub 2012 Jul 24.

18.

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.

Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA.

Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000.

PMID:
22799589
19.

Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.

Krishna G, Ma L, Martinho M, O'Mara E.

Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201. doi: 10.1128/AAC.00222-12. Epub 2012 May 21.

20.

Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.

Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J.

Hepatology. 2012 Nov;56(5):1622-30. doi: 10.1002/hep.25831. Epub 2012 Oct 14.

PMID:
22576324
21.

Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.

Krishna G, Ma L, Prasad P, Moton A, Martinho M, O'Mara E.

Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):1-10. doi: 10.1517/17425255.2012.639360. Epub 2011 Dec 19.

PMID:
22176629
22.

Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.

Kasserra C, Li J, March B, O'Mara E.

Clin Ther. 2011 Oct;33(10):1503-14. doi: 10.1016/j.clinthera.2011.08.012. Epub 2011 Oct 19.

PMID:
22015327
23.

Positively biased appraisals in everyday life: when do they benefit mental health and when do they harm it?

O'Mara EM, McNulty JK, Karney BR.

J Pers Soc Psychol. 2011 Sep;101(3):415-432. doi: 10.1037/a0023332.

24.

Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

Kasserra C, O'Mara E.

Clin Pharmacokinet. 2011 Apr;50(4):267-80. doi: 10.2165/11584560-000000000-00000.

PMID:
21348539
25.

Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.

Kasserra C, Sansone-Parsons A, Keung A, Tetteh E, Assaf M, O'Mara E, Marbury T.

Clin Pharmacokinet. 2010 Jun;49(6):397-406. doi: 10.2165/11319470-000000000-00000.

PMID:
20481650
26.

Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.

O'Mara E, Kasserra C, Huddlestone JR, Wan Y, Soni P, Caceres M, Medlock M, Morrison R, Devinsky O.

Antimicrob Agents Chemother. 2010 Jun;54(6):2448-54. doi: 10.1128/AAC.01447-09. Epub 2010 Mar 29.

27.

Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment.

Moton A, Krishna G, Ma L, O'Mara E, Prasad P, McLeod J, Preston RA.

Curr Med Res Opin. 2010 Jan;26(1):1-7. doi: 10.1185/03007990903364657.

PMID:
19886860
28.

Short-term administration of the CCR5 antagonist vicriviroc to patients with HIV and HCV coinfection is safe and tolerable.

Fätkenheuer G, Hoffmann C, Slim J, Rouzier R, Keung A, Li J, Treitel M, Sansone-Parsons A, Kasserra C, O'Mara E, Schürmann D.

J Acquir Immune Defic Syndr. 2010 Jan;53(1):78-85. doi: 10.1097/QAI.0b013e3181bb28dc.

PMID:
19838130
30.

Benevolent cognitions as a strategy of relationship maintenance: "don't sweat the small stuff".... But it is not all small stuff.

McNulty JK, O'Mara EM, Karney BR.

J Pers Soc Psychol. 2008 Apr;94(4):631-46. doi: 10.1037/0022-3514.94.4.631.

PMID:
18361676
31.

The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers.

Yan JH, Marino MR, Smith RA, Kanamaluru V, O'Mara EM, Grasela DM.

J Clin Pharmacol. 2006 Feb;46(2):193-200.

PMID:
16432271
32.

Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction.

Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, Shi J, Wang Y, O'Mara E.

AIDS. 2005 Oct 14;19(15):1635-41.

PMID:
16184033
33.

The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.

Noor MA, Parker RA, O'Mara E, Grasela DM, Currie A, Hodder SL, Fiedorek FT, Haas DW.

AIDS. 2004 Nov 5;18(16):2137-44.

PMID:
15577646
34.

Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads.

Damle BD, Yan JH, Behr D, O'Mara E, Nichola P, Kaul S, Knupp C.

J Clin Pharmacol. 2002 Apr;42(4):419-27.

PMID:
11936567
35.

Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.

Drusano GL, Bilello JA, Preston SL, O'Mara E, Kaul S, Schnittman S, Echols R.

J Infect Dis. 2001 Apr 1;183(7):1126-9. Epub 2001 Mar 1.

PMID:
11237841
36.

The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD.

Clin Pharmacol Ther. 1998 Aug;64(2):133-43.

PMID:
9728893
37.

Prevention of experimental Haemophilus ducreyi infection: a randomized, controlled clinical trial.

Thornton AC, O'Mara EM Jr, Sorensen SJ, Hiltke TJ, Fortney K, Katz B, Shoup RE, Hood AF, Spinola SM.

J Infect Dis. 1998 Jun;177(6):1608-13.

PMID:
9607840
38.

Use of an estimation method to derive an appropriate denominator to calculate central venous catheter-associated bloodstream infection rates.

Cookson ST, Ihrig M, O'Mara EM, Hartstein AI, Jarvis WR.

Infect Control Hosp Epidemiol. 1998 Jan;19(1):28-31. Erratum in: Infect Control Hosp Epidemiol 1998 May;19(5):304.

PMID:
9475346
39.

Increased bloodstream infection rates in surgical patients associated with variation from recommended use and care following implementation of a needleless device.

Cookson ST, Ihrig M, O'Mara EM, Denny M, Volk H, Banerjee SN, Hartstein AI, Jarvis WR.

Infect Control Hosp Epidemiol. 1998 Jan;19(1):23-7.

PMID:
9475345
40.

Magnetic resonance imaging of traumatic cervical nerve injuries.

Wysoki M, Koenigsberg RA, Camras L, Ortiz O, O'Mara E, Faro SH.

J Neuroimaging. 1998 Jan;8(1):38-41.

PMID:
9442589
41.

Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.

Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, Hall SD.

Clin Pharmacol Ther. 1996 Oct;60(4):374-84.

PMID:
8873685
42.

Delayed onset of angioedema with angiotensin-converting enzyme inhibitors: case report and review of the literature.

O'Mara NB, O'Mara EM Jr.

Pharmacotherapy. 1996 Jul-Aug;16(4):675-9. Review.

PMID:
8840375
43.

Root resection and retrofill: defining objectives to achieve surgical success, Part III.

O'Mara E, Mounce R.

Dent Today. 1995 Aug;14(8):44, 46-9. Review.

PMID:
9540516
44.

Root resection and retrofill: defining objectives to achieve surgical success.

O'Mara E, Mounce R.

Dent Today. 1995 Jun;14(6):42, 44-7. Review. No abstract available.

PMID:
9540474
45.

Root resection and retrofill: defining objectives to achieve surgical success, Part I.

Mounce RE, O'Mara E, Nakamuta H, Barrett S.

Dent Today. 1995 Apr;14(4):74, 76-9. Review. No abstract available.

PMID:
9540678
46.

Combination gel-inflatable mammary prosthesis: appearance at CT.

O'Mara EM, Pennes DR, Argenta LC.

Radiology. 1989 Jan;170(1 Pt 1):78.

PMID:
2909124
47.

[STRUGGLE AGAINST SILENCE].

O'MARA E.

Ann Laringol Otol Rinol Faringol. 1963 Sep-Oct;62:503-4. Italian. No abstract available.

PMID:
14091288

Supplemental Content

Loading ...
Support Center